Q-omics provides the consensus-scored ZSCAN23 profile across patient tissues and cancer cell-line models. ZSCAN23 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ZSCAN23 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, ZSCAN23 RNA expression shows 19,582 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UCS, KIRC, and KIRP as cancer lineages where ZSCAN23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZSCAN23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZSCAN23 survival associations across molecular data types. ZSCAN23 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZSCAN23 RNA expression–survival associations across cancer types. High ZSCAN23 expression shows unfavorable associations in THCA and UCEC, but favorable associations in UCS, KIRC, UVM and LAML. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for ZSCAN23 RNA expression.
This table summarizes ZSCAN23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZSCAN23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZSCAN23 shows lower tumor expression in KIRC, THCA, STAD, BRCA, READ and COAD. The KIRC box plot shows higher ZSCAN23 RNA expression in normal versus tumor tissue (log2 FC = −0.330, t-test p < 0.001).
This table shows molecular features associated with ZSCAN23 in patient tissues and cancer cell lines. In patient samples, ZSCAN23 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ZSCAN23 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and SOFT_TISSUE.
